Arthur L. Reingold's record shows rare breadth and durability across four decades of field epidemiology. He was first author of the 1982 Lancet paper defining nonmenstrual toxic shock syndrome during the original TSS investigations , and senior author of the 1985 NEJM investigation that identified pasteurized milk as the vehicle in a Massachusetts listeriosis outbreak (49 patients, 29% mortality) . His later surveillance work quantified the population-level impact of conjugate vaccines: the 2003 NEJM PCV7 study (2,397 citations) , the 2011 NEJM decade-update on bacterial meningitis (1,081 citations) , and influential ACIP hepatitis B recommendations .
The supplied full-text record illustrates his methodological standard. In a population- and laboratory-based case-control study (181 adolescent cases, 199 friend/school controls, ABCs/MeningNet sites, 2006-2013), one dose of MenACWY-D was 69% effective overall (95% CI 51-80%), with effectiveness waning from 79% at <1 year to 61% at 3-<8 years; serogroup C VE was 77% but serogroup Y VE only 51% (95% CI 1-76%), and serogroup W VE could not be calculated due to sparse cases. The team used GEE models adjusting for underlying conditions and smoking, verified vaccination records, and ran conditional logistic regression as a sensitivity analysis, concluding a booster was warranted . This directly informed ACIP policy and demonstrates honest reporting of null-adjacent and imprecise strata (serogroup Y CI reaching 1%), a marker of low selective-reporting risk.
Strengths. Reingold's metrics are elite: h-index 102 with 40,976 citations over 365 papers (one record) and h-index 104 with 46,697 citations over ~400 works (OpenAlex), with sustained citation rates exceeding 1,500/year through 2026. His signature contribution is methodological: extracting valid effectiveness and etiologic signals from imperfect, low-incidence surveillance data using population-based active surveillance, case-control designs, and explicit bias analysis.
Blindspots and caveats. Most highly cited works place him as a middle author on large CDC/Emerging Infections Program consortia, so his individual intellectual contribution is hard to isolate from the surveillance infrastructure and CDC coauthors. Funding came through CDC cooperative agreements , and his long ACIP workgroup service aligns his output with institutional immunization policy consensus, which readers should weigh when interpreting uniformly favorable vaccine-effectiveness conclusions. Key uncertainties in the reviewed study itself: overlapping CIs across time strata mean the waning trend is suggestive rather than statistically definitive; no serogroup A cases occurred, so serogroup A VE is unknown; and friend/school control matching may introduce enrollment bias. These caveats are appropriately disclosed by the authors rather than hidden, which is itself evidence of scientific integrity.
What would change this assessment: independent replications finding substantially lower or non-waning MenACWY-D effectiveness, evidence of selective authorship credit, or unreproduced surveillance findings would lower the score. None is present in the supplied record. Confidence: high on bibliometrics and the primary study (sourced full text); moderate on attributing consortium papers' methods specifically to Reingold.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.